UPDATE: Wedbush Starts Novan (NOVN) at Outperform

October 17, 2016 7:41 AM EDT
Get Alerts NOVN Hot Sheet
Price: $22.95 +1.15%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 10
Trade NOVN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Updated - October 17, 2016 7:43 AM EDT)

(update reflects correct firm name)

Wedbush initiates coverage on Novan (NASDAQ: NOVN) with a Outperform rating and a price target of $27.00.

Analyst David Nierengarten commented, "NOVN shares are expected to experience major near-term catalysts, including Ph 3 readout of SB204 in acne in 1Q17 and Ph 2 SB206 data in genital warts by YE16. We expect positive Ph 3 data that highlights SB204’s differentiated clinical profile, leading to first pass approval in late 2018 and launch soon after in the ~$5B domestic prescription acne market. Successful readout should also trigger partnership interest, although we view NOVN as capable of building the commercial infrastructure to launch the product on its own."

For an analyst ratings summary and ratings history on Novan click here. For more ratings news on Novan click here.

Shares of Novan closed at $18.97 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Credit Suisse

Add Your Comment